Latest Breaking News On - Faculty of medical sciences at newcastle university - Page 1 : comparemela.com

Iptacopan Reduces Proteinuria, Demonstrates Benefit in C3 Glomerulopathy

In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.

G steering committee member david kavanaghEuropean renal association congressFoundation trust david kavanaghFaculty of medical sciences at newcastle universityDavid kavanaghSteering committee member david kavanaghComplement therapeuticsHonorary consultant nephrologistMedical sciencesEuropean renal association

David Kavanagh, MBChB, PhD: Iptacopan Offers Hope for C3 Glomerulopathy

A Q&A with David Kavanagh, MBChB, PhD, on the results of the APPEAR-C3G trial and implications for care moving forward.

David kavanaghEuropean renal association congressFaculty of medical sciences at newcastle universityFoundation trust david kavanaghComplement therapeuticsHonorary consultant nephrologistMedical sciencesEuropean renal association

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35 1% proteinuria reduction vs placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label.

Czech republicUnited statesParag mahantiDavid soergelPrnewswire novartisMarianne silkjMarlena abdinoorJonathan grahamDavid kavanaghSloan simpsonFaculty of medical sciences at newcastle universityUniversity of washingtonG steering committee memberMetabolism development unitEuropean renal associationNovartis pharmaceuticals corporation

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35 1% proteinuria reduction vs placebo

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35 1% proteinuria reduction vs placebo
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United statesCzech republicImke kappesJonathan grahamMarlena abdinoorDavid kavanaghNicole zinsli sommParag mahantiMarianne silkjSatoshi sugimotoDavid soergelIsabella zinckSloan simpsonMichael meoExchange commissionUniversity of washington

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35 1% proteinuria reduction vs placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2

United statesCzech republicImke kappesMarlena abdinoorDavid soergelMichael meoSloan simpsonJonathan grahamParag mahantiIsabella zinckMarianne silkjDavid kavanaghNicole zinsli sommSatoshi sugimotoFaculty of medical sciences at newcastle universityGlomerular diseases work group